Cellosaurus logo
expasy logo

Cellosaurus Mel1617 (CVCL_DG51)

[Text version]
Cell line name Mel1617
Synonyms MEL1617; Mel-1617
Accession CVCL_DG51
Resource Identification Initiative To cite this cell line use: Mel1617 (RRID:CVCL_DG51)
Comments Part of: Wistar Institute melanoma cell line collection.
Population: Caucasian.
Omics: Array-based CGH.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=21156289).
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289).
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_DG52 (Mel1617-BR)CVCL_DG53 (Mel1617-MR)
Originate from same individual CVCL_7928 ! WM164
Sex of cell Male
Age at sampling 22Y
Category Cancer cell line
Publications

PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023
Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M.
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Cancer Cell 18:683-695(2010)

PubMed=23285177; DOI=10.1371/journal.pone.0052760
Schayowitz A.B., Bertenshaw G.P., Jeffries E., Schatz T., Cotton J., Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H., Schuchter L.M., Clark D.P.
Functional profiling of live melanoma samples using a novel automated platform.
PLoS ONE 7:E52760-E52760(2012)

PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023
Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M., Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A., Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K., DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C., Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X.-W., Schuchter L.M., Herlyn M., Nathanson K.L.
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Cell Rep. 4:1090-1099(2013)

Cross-references
Cell line databases/resources cancercelllines; CVCL_DG51
Encyclopedic resources Wikidata; Q54905149
Gene expression databases GEO; GSM1199180
Polymorphism and mutation databases Progenetix; CVCL_DG51
Entry history
Entry creation13-Jul-2016
Last entry update05-Oct-2023
Version number11